- Report
- June 2024
- 70 Pages
France
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
China
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
Brazil
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
Europe
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
Latin America
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
Asia Pacific
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
North America
From €858EUR$950USD£734GBP
- Report
- June 2024
- 70 Pages
Global
From €858EUR$950USD£734GBP
- Report
- April 2024
- 132 Pages
Global
From €858EUR$950USD£734GBP
- Report
- June 2023
- 132 Pages
Global
From €858EUR$950USD£734GBP
- Book
- April 2018
- 486 Pages
- Book
- June 2019
- 304 Pages
- Book
- January 2016
- 472 Pages
- Book
- November 2013
- 744 Pages
- Book
- March 2021
- 320 Pages
- Book
- February 2021
- 544 Pages

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more